Genor Biopharma Executive and Leadership Team

Feng Guo, the Chief Executive Officer at Genor Biopharma, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the development of 15 targeted drug candidates, the Chief Executive Officer ensures alignment between research initiatives and commercialization goals. This leadership role involves managing high-level partnerships and driving expansion within the competitive biopharmaceutical sector. By prioritizing innovation in oncology and autoimmune drug development, Feng Guo secures the company's position as a leader in the global market. The Chief Executive Officer maintains rigorous oversight of the pipeline to ensure that novel biological pathways receive adequate funding and resources. Through strategic decision-making, the Chief Executive Officer fosters a culture of excellence that supports the mission of serving patients and society. Ultimately, Guo drives the growth of the enterprise while maintaining a focus on sustainable therapeutic advancement and long-term value creation for all stakeholders involved in the biopharmaceutical ecosystem.

Weng Chengyi, the Executive Director & Chief Financial Officer at Genor Biopharma, manages the financial health and capital allocation strategies of the organization. Overseeing the budgeting process and investor relations, the Executive Director & Chief Financial Officer ensures that the company maintains the necessary liquidity to fund its 15 drug candidates. This leadership role involves analyzing market trends and financial risks to support sustainable growth. By providing fiscal oversight, Weng Chengyi enables the research and development teams to pursue novel biological pathways without interruption. The Executive Director & Chief Financial Officer collaborates with the Board to ensure transparency and compliance with financial regulations. Through the management of capital resources, the Executive Director & Chief Financial Officer supports the long-term commercialization goals of the firm. Ultimately, Chengyi drives the financial stability of the company, ensuring that all fiscal activities align with the broader mission of delivering innovative oncology and autoimmune treatments to the global market.

Paul Ni, the Chief Operating Officer (Genor Biopharma) at Genor Biopharma, manages the internal operational frameworks and supply chain logistics necessary for drug commercialization. Overseeing the execution of manufacturing processes, the Chief Operating Officer (Genor Biopharma) ensures that the company meets the high demand for oncology and autoimmune therapies. This leadership role involves streamlining cross-departmental workflows to maximize productivity and operational efficiency. By optimizing the production of drug candidates, Paul Ni supports the company's ability to serve patients effectively. The Chief Operating Officer (Genor Biopharma) coordinates with external partners to ensure the seamless delivery of products across regional markets. Through the implementation of robust operational standards, the Chief Operating Officer (Genor Biopharma) maintains the integrity of the supply chain and supports the overall growth strategy. Ultimately, Ni drives the operational success of the firm, ensuring that all internal systems function in harmony to support the development and distribution of innovative medical therapies.

Qibin Liang, the Chief Technology Officer at Genor Biopharma, architects the technical infrastructure and research methodologies required for drug discovery. Overseeing the integration of advanced biological platforms, the Chief Technology Officer ensures that the pipeline remains at the forefront of scientific innovation. This leadership role involves managing laboratory operations and optimizing the development of targeted drug candidates. By implementing cutting-edge research tools, Qibin Liang accelerates the transition from novel biological pathways to viable therapeutic solutions. The Chief Technology Officer collaborates with the research teams to refine the technical processes necessary for successful commercialization. Through the application of sophisticated data analysis and scientific rigor, the Chief Technology Officer enhances the efficiency of the drug development lifecycle. Ultimately, Liang drives the technological capabilities of the firm, ensuring that the research department maintains a competitive edge in the global biopharmaceutical landscape while consistently delivering high-quality scientific results.

Li Tong, the Chief Medical Officer at Genor Biopharma, directs the clinical development programs and regulatory strategy for the company's drug pipeline. Overseeing the design and execution of clinical trials, the Chief Medical Officer ensures that all therapeutic candidates meet the highest safety and efficacy standards. This leadership role involves managing interactions with regulatory bodies to facilitate the approval of oncology and autoimmune drugs. By leading the clinical team, Li Tong ensures that the development of novel biological pathways remains grounded in rigorous medical science. The Chief Medical Officer collaborates with the research department to translate scientific discoveries into patient-centered therapies. Through the oversight of clinical data, the Chief Medical Officer validates the commercial potential of the drug candidates. Ultimately, Tong drives the medical strategy of the firm, ensuring that all clinical activities support the overarching goal of providing innovative and effective treatments to patients in need across the global biopharmaceutical landscape.